|
|
|
|
| LEADER |
01583nam a2200265 u 4500 |
| 001 |
EB002001281 |
| 003 |
EBX01000000000000001164182 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Brett, Kendra
|
| 245 |
0 |
0 |
|a Treatment of tuberculosis
|h Elektronische Ressource
|b a review of guidelines
|c Kendra Brett, Camille Dulong, Melissa Severn
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, March 6, 2020
|
| 300 |
|
|
|a 1 PDF file (47 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 700 |
1 |
|
|a Dulong, Camille
|e [author]
|
| 700 |
1 |
|
|a Severn, Melissa
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK562947
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This report is part of series of evidence reviews on TB guidelines and can serve as a guidance document to identify which guidelines include recommendations for the treatment of latent and active TB and the strength of the guidelines. This report does not cover recommendations regarding the treatment of multi-drug resistant TB, or treating TB in people with HIV or conditions that compromise the immune system, as these topics are covered in separate reports. This report focuses on treatment strategies for LTBI and active TB disease
|